Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients - Wikidata - awgldk - TriplyDB

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

http://www.wikidata.org/entity/Q28066710

about

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

P2860

Q30275582-571B40E7-FA10-44AB-A796-698CC6BEEF21 Q38996724-04731964-64FF-4C53-B356-49301C01D188 Q39044162-65903624-3921-4B40-8F9B-F0EA79670E19 Q40216708-D2D9215A-1844-48FB-ABA8-F4A887EBC583 Q40274310-DC80FE2D-7837-4F60-849E-5FD52B8E7AA9

P2860

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

http://www.wikidata.org/entity/Q28066710

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@ast

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@en

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@nl

type

label

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@ast

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@en

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@nl

prefLabel

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@ast

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@en

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@nl

P1433

Q28066710-D9EDA749-3EA6-4361-A5E5-42714B7E3255

P1476

Q28066710-1D2BB363-46E5-4C2B-AE91-E26E73D8D66C

P2093

Q28066710-09D8B035-D9E2-4FD1-B456-2AEB8C1DFD8D

Q28066710-0DC25435-84C1-4F9C-B328-F491C857D127

Q28066710-437E4B51-117A-48E5-B548-E83F4B612C71

Q28066710-5A51FF50-59E6-4C4D-8324-82E4F1D5E588

Q28066710-AEA35E08-31AE-47F9-8BDB-DFB6E2EEC992

Q28066710-CFBFEBED-701E-4611-8A0F-AB2C9FA6E4C3

Q28066710-D6CFA6BA-5A84-44BC-B61E-62AB350C648C

Q28066710-FC5B7525-65C2-49B3-8FD6-0898581F0BCF

P2860

Q28066710-00C775A0-4CF3-454B-9D80-D40C52B155CF

Q28066710-02349B9C-7649-4FB1-B805-C7C2EE0B28B7

Q28066710-03CAD6FE-61DE-4C61-AB55-20BF17348AE6

Q28066710-07E21636-A393-4571-A6E1-254F5B82A997

Q28066710-0C7CB8E2-6B09-427C-B987-01855D361B59

Q28066710-149D02D3-9AF4-4B41-BBDA-D109F4171915

Q28066710-18B66675-298B-4C61-A378-CD0A65443AB5

Q28066710-1AC576FA-0D01-4370-B13A-D1C2DFF32194

Q28066710-1ADAD0B4-22F7-43C0-92B0-0183531140E7

Q28066710-1BAB7763-14A5-4348-9411-F704F5465F29

P304

Q28066710-9DE49C5F-AE75-4616-8F76-0851085D866C

P31

Q28066710-5E79B277-BF50-4D61-84DD-73F5ED1D232E

P356

Q28066710-7F67F0E9-BCFC-4C29-AF1F-770929DE1575

P407

Q28066710-7E3D1113-DB5A-42C4-B259-F422A5F81277

P433

Q28066710-777D25B0-F1FB-46D9-A78E-3B1D9374D891

P478

Q28066710-116F26A3-025E-430B-9E49-4C4F1B451397

P50

Q28066710-1BF0A131-D327-432F-AEB2-09B409E73443

Q28066710-2717B1C3-2FE0-483C-9392-5CCA2AF1BA7E

P577

Q28066710-41971DC3-9F7F-457A-BA92-063307282DE4

P698

Q28066710-DC5EC339-2B0F-4C56-BE6B-AD8A15F3648D

P932

Q28066710-81291329-4E3E-4A51-9904-6088640CBF90

P356

J.BBMT.2016.04.019

P1433

Biology of Blood and Marrow Transplantation

P1476

Allogeneic Hematopoietic Cell ...... Application to Older Patients

@en

P2093

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Christopher Bredeson

http://www.w3.org/2001/XMLSchema#string

Effie Petersdorf

http://www.w3.org/2001/XMLSchema#string

Hillard M Lazarus

http://www.w3.org/2001/XMLSchema#string

Jonathon B Cohen

http://www.w3.org/2001/XMLSchema#string

Luciano J Costa

http://www.w3.org/2001/XMLSchema#string

Mehdi Hamadani

http://www.w3.org/2001/XMLSchema#string

Timothy S Fenske

http://www.w3.org/2001/XMLSchema#string

P2860

Follicular lymphoma: 2014 update on diagnosis and management

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

P304

1543-1551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2016.04.019

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27131863

http://www.w3.org/2001/XMLSchema#string

P932

4981559

http://www.w3.org/2001/XMLSchema#string